160 related articles for article (PubMed ID: 16249697)
1. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss.
Schüpbach J; Günthard H; Joos B; Fischer M; Böni J; Tomasik Z; Yerly S; Perrin L; Battegay M; Furrer H; Vernazza P; Bernasconi E; Hirschel B;
J Acquir Immune Defic Syndr; 2005 Nov; 40(3):250-6. PubMed ID: 16249697
[TBL] [Abstract][Full Text] [Related]
2. Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.
Plana M; Garcia F; Oxenius A; Ortiz GM; Lopez A; Cruceta A; Mestre G; Fumero E; Fagard C; Sambeat MA; Segura F; Miró JM; Arnedo M; Lopalcos L; Pumarola T; Hirschel B; Phillips RE; Nixon DF; Gallart T; Gatell JM
J Acquir Immune Defic Syndr; 2004 Jul; 36(3):791-9. PubMed ID: 15213562
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy.
Schüpbach J; Böni J; Bisset LR; Tomasik Z; Fischer M; Günthard HF; Ledergerber B; Opravil M;
J Acquir Immune Defic Syndr; 2003 Jul; 33(3):292-9. PubMed ID: 12843739
[TBL] [Abstract][Full Text] [Related]
4. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
[TBL] [Abstract][Full Text] [Related]
5. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.
García F; Plana M; Ortiz GM; Bonhoeffer S; Soriano A; Vidal C; Cruceta A; Arnedo M; Gil C; Pantaleo G; Pumarola T; Gallart T; Nixon DF; Miró JM; Gatell JM
AIDS; 2001 Jun; 15(9):F29-40. PubMed ID: 11416735
[TBL] [Abstract][Full Text] [Related]
6. Simple monitoring of antiretroviral therapy with a signal-amplification-boosted HIV-1 p24 antigen assay with heat-denatured plasma.
Böni J; Opravil M; Tomasik Z; Rothen M; Bisset L; Grob PJ; Lüthy R; Schüpbach J
AIDS; 1997 May; 11(6):F47-52. PubMed ID: 9143600
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus-type 1 specific cellular immunity in chronic infected patients on prolonged highly active antiretroviral treatment and on structured treatment interruption.
Matsuda R; Boström AC; Fredriksson M; Fredriksson EL; Bratt G; Hejdeman B; Sandström E; Okuda K; Wahren B
Microbiol Immunol; 2006; 50(8):629-35. PubMed ID: 16924148
[TBL] [Abstract][Full Text] [Related]
8. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
Ruiz L; Martinez-Picado J; Romeu J; Paredes R; Zayat MK; Marfil S; Negredo E; Sirera G; Tural C; Clotet B
AIDS; 2000 Mar; 14(4):397-403. PubMed ID: 10770542
[TBL] [Abstract][Full Text] [Related]
9. Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression.
Orenstein JM; Bhat N; Yoder C; Fox C; Polis MA; Metcalf JA; Kovacs JA; Falloon J; Walker RE; Masur H; Lane HC; Davey RT
AIDS; 2000 Aug; 14(12):1709-15. PubMed ID: 10985306
[TBL] [Abstract][Full Text] [Related]
10. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
[TBL] [Abstract][Full Text] [Related]
11. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
[TBL] [Abstract][Full Text] [Related]
12. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
Foli A; Maserati R; Barasolo G; Castelli F; Tomasoni L; Migliorino M; Maggiolo F; Pan A; Paolucci S; Scudeller L; Tinelli C; D'Aquila R; Lisziewicz J; Lori F
Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
14. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.
Carcelain G; Tubiana R; Samri A; Calvez V; Delaugerre C; Agut H; Katlama C; Autran B
J Virol; 2001 Jan; 75(1):234-41. PubMed ID: 11119593
[TBL] [Abstract][Full Text] [Related]
15. [Effects of traditional Chinese medicine on CD4 + T cell counts and HIV viral loads during structured treatment interruption in highly active antiretroviral therapy].
Zhao HX; Zhang FJ; Han N; Lan MD; Yao J; Liu ZY; Lu LH; Wei HS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Oct; 28(5):658-61. PubMed ID: 17121226
[TBL] [Abstract][Full Text] [Related]
16. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
[TBL] [Abstract][Full Text] [Related]
17. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
[TBL] [Abstract][Full Text] [Related]
19. Changes in immunoglobulin isotypes and immunoglobulin G (IgG) subclasses during highly active antiretroviral therapy: anti-p24 IgG1 closely parallels the biphasic decline in plasma viremia.
Voltersvik P; Albrektsen G; Ulvestad E; Dyrhol-Riise AM; Sørensen B; Asjö B
J Acquir Immune Defic Syndr; 2003 Dec; 34(4):358-67. PubMed ID: 14615653
[TBL] [Abstract][Full Text] [Related]
20. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
